CD4 and neoplasm: Patients in whom glioblastomas were surgically resected received another personalized peptide neoantigen vaccine that elicited neoantigen-specific CD4+ and CD8+ T-cell responses and showed an accumulation of neoantigen-specific T cells in the tumor site [193].